Caplin Group commences operations of Rs. 150 crore oncology facility
The facility will manufacture tablets, capsules, and injections for the oncology segment
The facility will manufacture tablets, capsules, and injections for the oncology segment
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Ayush is expanding beyond wellness to therapeutic wellness
Subscribe To Our Newsletter & Stay Updated